The Food and Drug Administration yesterday updated its Risk Evaluation and Mitigation Strategy for extended-release and long-acting opioid analgesics, and extended the same requirements to immediate-release opioid analgesic products. The REMS applies to 347 opioid analgesics intended for outpatient use. Among other changes, the updates modify the prescriber education blueprint to include more information on pain management and require manufacturers to make training available to other, non-physician prescribers, such as nurses and pharmacists involved in pain management. FDA announced the planned updates last year. In other news, the Centers for Disease Control and Prevention recently released a resource to help health care providers implement its guidelines for prescribing opioids for chronic pain.

Related News Articles

Headline
The Health Resources and Services Administration yesterday awarded 80 rural consortia $1 million each to help prevent, treat and support recovery for patients…
Headline
The National Association of Attorneys General yesterday urged congressional leaders to remove federal barriers to opioid use disorder treatment.
Headline
The number of naloxone prescriptions dispensed from retail pharmacies doubled in 2018, but access to the emergency opioid overdose treatment still varies…
Headline
The Department of Health and Human Services seeks input from health care providers and other stakeholders for a report to Congress on ensuring legitimate…
Headline
The Department of Health and Human Services yesterday sent Congress its plan to help states develop and expand innovative strategies to provide housing-related…
Headline
Qualified nonprofits and government agencies may submit through Aug. 25 letters of intent to apply for funding from the Foundation for Opioid Response Efforts…